Caribou Biosciences to Present First Clinical Data from Dual Allogeneic CAR-T Programs in Lymphoma and Multiple Myeloma
核心洞察
Caribou Biosciences will host a webcast on November 3, 2025, to present new data from the ANTLER Phase 1 trial of vispa-cel in relapsed/refractory B-cell non-Hodgkin lymphoma.
The company will report first clinical data from the CaMMouflage Phase 1 trial evaluating CB-011, an allogeneic anti-BCMA (搜索) CAR-T therapy, in patients with relapsed/refractory multiple myeloma.
Caribou will outline its anticipated pivotal Phase 3 trial design for vispa-cel and next steps for CB-011's continued clinical development.
Caribou Biosciences, Inc. (Nasdaq: CRBU) announced it will hold a webcast beginning at 8:00 am ET on Monday, November 3, 2025, to report new clinical data from two allogeneic CAR-T cell therapy programs targeting hematologic malignancies. The clinical-stage CRISPR genome-editing biopharmaceutical company will present updated results from its ANTLER Phase 1 trial evaluating vispacabtagene regedleucel (搜索) (vispa-cel; formerly CB-010) in patients with relapsed or refractory B cell non-Hodgkin lymphoma (搜索) (r/r B-NHL), alongside the first clinical data from its CaMMouflage Phase 1 trial of CB-011 in patients with relapsed or refractory multiple myeloma (搜索).
Vispa-cel Advances Toward Pivotal Trial
Vispacabtagene regedleucel (搜索) represents an allogeneic anti-CD19 (搜索) CAR-T cell therapy being evaluated in the ANTLER Phase 1 clinical trial (NCT04637763) for patients with relapsed or refractory B cell non-Hodgkin lymphoma (搜索). According to Caribou, vispa-cel is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 (搜索) knockout, a genome-editing strategy designed to enhance CAR-T cell activity by limiting premature CAR-T cell exhaustion.
The therapy has received significant regulatory recognition from the FDA, including Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations for B-NHL. The company will present its anticipated pivotal Phase 3 trial design for vispa-cel during the webcast, marking a critical milestone in the therapy's development pathway.
The ANTLER study employs a non-randomized, single-group intervention model consisting of two parts: a dose-escalation phase to determine the optimal dose, followed by an expansion phase. The study began on November 16, 2020, with primary completion expected in 2025, and aims to evaluate the safety, emerging efficacy, pharmacokinetics, and immunogenicity of the CRISPR-edited therapy.
CB-011 Debuts with Immune Cloaking Technology
CB-011, an allogeneic anti-BCMA (搜索) CAR-T cell therapy, will make its clinical data debut with results from the CaMMouflage Phase 1 trial (NCT05722418) in patients with relapsed or refractory multiple myeloma (搜索). Caribou states that CB-011 is the first allogeneic CAR-T cell therapy in the clinic engineered to enable activity through an immune cloaking strategy with a B2M knockout and insertion of a B2M–HLA-E fusion protein to blunt immune-mediated rejection.
The FDA has granted CB-011 Fast Track and Orphan Drug designations, recognizing its potential to address significant unmet medical needs in multiple myeloma treatment. The company will also outline next steps for CB-011's continued clinical development during the presentation.
CRISPR Platform Technology
Both therapies leverage Caribou's genome-editing platform, including its Cas12a chRDNA technology, which the company describes as enabling superior precision to develop cell therapies that are armored to potentially improve activity against diseases. The company positions these off-the-shelf CAR-T cell therapies as having the potential to provide broad access and rapid treatment for patients with hematologic malignancies.
The live webcast will be accessible via Caribou's website on the Events page, with an archived version available for 30 days after the event. The presentation represents a significant milestone for the Berkeley, California-based company as it advances two distinct allogeneic CAR-T programs through clinical development.